(Q46760321)

English

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study

scientific article published in September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

3

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

Gavin Giovannoni

5

object named as

Gavin Giovannoni

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

Krzysztof Selmaj

6

object named as

Krzysztof Selmaj

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

2

object named as

Ralf Gold

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

1

object named as

Amit Bar-Or

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

Douglas L Arnold

4

object named as

Douglas L Arnold

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

Katherine S. Dawson

9

object named as

Katherine T Dawson

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

author name string

John O'Gorman

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

Monica Stephan

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

publication date

1 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

260

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

2297-2305

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

https://scigraph.springernature.com/pub.10.1007/s00415-013-6954-7

0 references

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Clinical prognostic factors in multiple sclerosis: a natural history review

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Natural history of multiple sclerosis: early prognostic factors.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Natural history of multiple sclerosis: long-term prognostic factors

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Relapses in multiple sclerosis are age- and time-dependent

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6954-7

21 January 2018

Short-term prognosis in early relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity in multiple sclerosis: scratching the surface of a complex disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis--preliminary results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23797999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-013-6954-7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/23797999

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46760321&oldid=2130253485"